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Two analogues of the loop diuretics furosemide and bumeta~de have been identifi~ as dil%rential in~bitors of KC1 and NaKCl cotransport 
systems, assayed by measuring K+ influx in ‘young’ human red cells. HZ5 inhibited both NaKCl and KC1 cotransport, with Z,,, values of 0.03 
and 30 PM respectively; H74 had no effect on NaKCl cotransport, even at 0.3 mM, but inhibited KC1 cotransport with an I,,% of 75 PM. These 
compounds are therefore useful for resolving the two transport systems. 
K+ transport; Red cell; HbSS 
1. INTRODUCTION 
The coupled KC1 cotransport system has been 
described in the plasma membranes of a number of cell 
types (red cells, hepatocytes, ascites tumour cells, 
epithelia, thick ascending limb of the loop of Henle 
[I-S]), and has been shown to play a major role in 
regulatory volume decrease (RVD) following cell swell- 
ing. Although there is a variety of experimental 
manoeuvres capable of activating this pathway (N- 
ethylm~eimide treatment, ghosting, hy~ostatic pres- 
sure [6-91) studies of its properties have been hindered 
by the lack of specific inhibitors, although recently cer- 
tain aryloxyalkenoic acid derivatives have been iden- 
tified as inhibitors for this system [lo]. 
cotransport with a considerably higher affinity [l], The 
differential sensitivity to these diuretics has been used 
as a criterion to separate KC1 from NaKCl cotransport 
activity (see [ 11). We have taken advantage of the obser- 
vation of partial inhibition by high concentrations 
(> 0.5 mM) of ‘loop’ diuretics on KC1 cotransport (e.g. 
[l]) to screen structural analogues of these compounds 
for enhanced potency against this system. 
Volume-sensitive KC1 cotransport can mediate a 
powerful RVD response in normal (i.e. HbAA) ‘young’ 
human erythrocytes, but the activity of this pathway is 
dramatically attenuated with cell maturation [ 1 , 1 1,121. 
In certain cases of haemoglobinopathy (e.g. HbSS) the 
KC1 pathway is operational in much of the cell popula- 
tion, mainly because a large fraction of the total red cell 
population consists of reticulocytes and ‘young’ red 
cells, due to increased cell turnover. Swelling these red 
cells either osmotically or by acidification results in a 
large K+ efflux of up to 50 mmol/l cells/h via this 
pathway [I 3-l 51, This could cause cellular dehydration, 
an increased MCHC, and in the case of HbSS cells, an 
enhanced risk of sickling 1161. 
In this paper we present data on two compounds out 
of 165 analogues of bumetanide and furosemide which 
we have screened as inhibitors of the two Cl--de- 
pendent K+ transport systems (NaKCl and KC1 co- 
transport). Experiments have been carried out either on 
‘young’ cell-enriched fractions of blood (HbAA), 
prepared by centrifugation from haemochromatotic pa- 
tients, or on red cells obtained from donors with sickle 
cell disease (HbSS). These red cells express normal 
levels of NaKCl cotransport activity, but elevated KC1 
cotransport [13]. We have identified two molecules 
designated H25 and H74, which act differentially; H25 
has a high affinity for NaKCl cotransport inhibition, 
and a lower, but significant affinity for KC1 cotrans- 
port; in contrast H74 is completely ineffective on 
NaKCl cotransport, but has a significant inhibitory ef- 
fect on KC1 cotransport. 
2. MATERIALS AND METHODS 
2.1. Blood 
The ‘loop’ diuretics furosemide and bumetanide are 
poor inhibitors of KC1 cotransport, but inhibit NaKCl 
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Blood (HbAA) from haemochromatosis patients was taken into 
heparin, and washed three times by centrifugation (2500 x g; 15 min, 
S°C) with a medium containing (in mM); NaCl (150); MOPS (15); 
glucose (5); 300 mOsm, pH 7.4). To separate a ‘young’ cell enriched 
cell population, the loosely packed cells (about 808 haematocrit) 
were divided between twenty 10 ml tubes and spun at 2500 x g for 1 
hat 20°C. The top third of cells was then carefully harvested, and put 
into 6 tubes for a recentrifugation. The top third of this second 
separation was harvested, yielding about 15 ml of ‘young’ cell- 
enriched cell suspension [17]. HbSS blood was obtained as 10 ml 
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samples taken into lithium heparin, and stored on ice for less than 12 
h before use. 
2.2. ~effsu~e~e~i of K’ and Na+ .fkxes 
K+ uptake experiments, using 86Rb as a congener, were performed 
using standard techniques as described previously [12,18]. Briefly, red 
cells at about 5% haematocrit, suspended in the saline described 
above, were pretreated with ouabain (0.1 mM) in the presence of 
either water or 1 M sucrose so that the cells were swollen or shrunken 
respectively by about 12%. The flux was started by the addition of 
isotonic KC1 (including 86Rb to give a final K+ concen~ation of 7.5 
mM, and radioactivity of about 2 &i/ml cell suspension). The in- 
cubation period was 10 min, after which the cells were washed four 
times by centrifugation (10000 x g; 15 s), by aspiration and addition 
of ice-cold medium comprising (mM) : MgC12 (106); MOPS (15); pH 
7.4. The final cell pellet was lysed with 0.5% (v/v) Triton X-100 in 
water, deproteinised with 5% TCA (w/v), centrifuged and the super- 
natant counted for radioactivity using Cerenkov radiation. Na+ up- 
take was measured in a medium containing (mM); NaCl(20); KC1 (20) 
N-methyl-D-glucamine Cl (110); MOPS (10); glucose (5); and oua- 
bain (0.1) (pH 7.4) with “Na at 5 &i/ml. Sodium uptake was 
measured over 30 min, the cells washed as above, and processed for 
,&scintillation counting. The replacement of Cl- by methylsulphate 
(CHsSOs-) was achieved by washing cells 3 times at 5°C with (mM); 
NaCH$Oo (165); glucose (5); MOPS (15) pH 7.4, incubating at 5% 
for 2 h, then washing 3 more times with the same solution. It was 
necessary to maintain the temperature low during this period because 
of the rapid disappearance of KC1 cotransport activity at higher 
temperatures [ 1, 1 11. The drugs studied were dissolved in water, or 
DMSO as appropriate. Controls for the effect of DMSO were includ- 
ed. NaKCl cotransport was defined as the fraction of Kf uptake in 
shrunken cells inhibitable by bumetanide (0.1 mM). KC1 cotransport 
was taken as the volume-sensitive component of K+ uptake, defined 
as the difference in K’ uptake between swollen and shrunken cells. 
fects of increasing concentrations of H25 and H74 on 
ouabain-insensitive K+ uptake in ‘young’ red cell- 
enriched fractions of blood are compared at two dif- 
ferent cell volumes. In shrunken cells, H25 inhibited Kf 
uptake at all concentrations tested (3-3OOpM). This in- 
hibition was equal to that observed by adding 
bumetanide to shrunken cells, and represents total sup- 
pression of the NaKCl cotransport pathway (see also 
fig.2a). In swoIlen cells, the NaKCl cotransport system 
only represents a minor component of the total K+ up- 
take which is dominated by the flux through the KC1 
cotransporter. It can be seen that H25 is also effective 
at inhibiting this component of K+ transport, although 
with a lower affinity. This behaviour is similar to the 
published effects of bumetanide and furosemide on the 
two transport systems 11,191. Fig.lb, in contrast, shows 
that H74 has no inhibitory effect on NaKCI cotransport 
at any concentration tested (3-300 PM), whilst it is an 
effective inhibitor of KC1 cotransport. 
A direct comparison of the inhibitory potency of the 
drugs H25 and H74 on the two transport me~h~isms 
showed that the 150% for H25 is 0.03 pM for NaKCl 
cotransport and 30 pM for KC1 cotransport. In con- 
trast, H74 had no effect on NaKCl cotransport, but in- 
hibited volume-sensitive K+ transport with an 150% of 
75 FM. 
2.3. Chemicals 
All inorganic salts were of analytical grade, and ouabain and 
MOPS were obtained from Sigma Chemical Co. Bumetanide was pro- 
vided by Leo Pharmaceuticals, and **Na and 86Rb were obtained 
from Amersham Internation~. The two molecules H25 and H74 were 
supplied by Hoechst Phatmaceuticals and are analogues of 
bumetanide; the chemical name of H25 is a 3-benzylamino-rl-phe- 
noxy-5-sulphamoylbenzoic a id, and that of H74 is 3-(2-(l-naphthyl)- 
ethyl)amino-4-phenoxy-5-sulphamoylbenzoid acid.
3. RESULTS AND DISCUSSION 
Although it is apparent from the results for shrunken 
cells (fig. lb) that these drugs do not markedly increase 
basal K+ permeability, we tested H74 in cells under 
Cl--free conditions (Cl- replaced by CH3S04-) where 
no KC1 or NaKCl activity was possible. Thus, in 
CH3S04- medium, K+ uptake was 0.219 t 0.004 and 
0.228 f 0.006 mmolf 1 cells/h in swollen and shrunken 
cells, respectively; in the presence of H74 (0.2 mM), the 
respective values were 0.239 + 0.006 and 0.234 + 
0.014 mmol/l cells/h, (results are means + SD for 
triplicate determinations from one of two similar ex- 
periments). This confirms that H74 did not induce a 
significant increase in K” leak. 
In preliminary experiments, the efficacy of the two An important control experiment was the effect of 
drugs for inhibition of KC1 cotransport (defined as the H25 and H74 on Na+ fluxes, where one would expect 
volume-sensitive component of 86Rb uptake) was tested that only H25 should inhibit Na+ uptake via the NaKCl 
at a single drug concentration (0.1 mM) on both HbAA cotransporter. In practice, measuring Na+ influx via 
(haemochromatosis) and HbSS red cells. KC1 NaKCl cotransport is difficult since there are several 
cotransport was inhibited by H74 by 58.2 + 8.9% parallel pathways, and its contribution to the total Naf 
(n = 6 donors; HbAA), and 54.2 f 2.4% (n = 5; flux is small. We have therefore measured Na+ uptake 
HbSS) respectively. H25 was more potent inhibiting under conditions chosen to minimise Na+ flux through 
78.0 + 6.9% (n = 5 donors), and 76.3 + 0.7% other pathways, in a low Na-containing solution (see 
(n = 3 donors) respectively. Equivalent results were section 2 for details). Thus, in one of two similar ex- 
obtained for inhibition of NaKCl cotransport in the two periments, control Na+ uptake was 0.498 +- 0.006; in 
cell types: fluxes in the presence of H74 being the presence of H74 (0.1 mM) it was 0.468 + 0.015, 
91.5 z~t 5% (HbAA, n = 8) and 96.7 + 5.0% (HbSS, whilst the addition of bumetanide (0.1 mM) reduced the 
n = 7) of the control values. From these experiments, flux to 0.327 + 0.009 mmol/l cells/h. In a further 
we conclude that there is no difference in the phar- series of experiments using H25 (0.1 mM) the control 
macological sensitivity of KC1 or NaKCl cotransport in Na+ flux was 0.444 k 0.005, this being reduced to 
HbAA or HbSS cells, and that H25 and H74 have clear 0.238 f 0.011 and 0.235 + 0.005 mmolll cells. h in 
differential effects on the two systems. In fig.1 the ef- the presence of H25 or bumetanide respectively (results 
216 
Volume 262, number 2 FEBSLETTERS March 1990 
(b) (a) 
12- 
6- 
2- 
SH 
P n 0 
1 I * I , 
0.1 0.2 0.3 0.1 0.2 0.3 
H25(mM) H74(mM) 
Fig. 1. The effect of (a) H25 and (b) H74 on K+ uptake in ‘young’ human red cells. The data for (a) were obtained from a haemochromatosis patient, 
and for (b) from a donor with HbSS red cells. Filled circles represent the flux measured in cells swollen (15%) hypotonically. Open circles represent 
the flux measured in cells shrunken by the addition of sucrose (final osmolarity 400 mOsm). The figure is representative of four similar experiments. 
are one of 6 similar experiments with data given as 
means + SD). Therefore, H25 completely inhibited the 
Na+ flux via NaKCl cotransport (as defined as that 
fraction inhibited by bumetanide (0.1 mM), whereas 
H74 showed only a very small effect. 
The present results identify two potentially useful 
molecules for separating NaKCl and KC1 cotransport 
activity. H25 is a potent inhibitor of NaKCl cotrans- 
port, and a reasonable inhibitor of KC1 cotransport. In 
contrast, H74 is without effect on NaKCl cotransport, 
but inhibits KC1 cotransport with a modest potency. 
The structural component responsible for the inhibitory 
efficacy is presumably the naphthyl residue in position 
2. This bulkier group can be tolerated by the KC1 
100 
%I 
50 
0 
KCI cotransport 
Log Concentration 
cotransporter, but not by the NaKCl cotransporter. In 
this context it is interesting to note that the KC1 
cotransporter prefers the larger Br- ion to Cl- (suppor- 
ting a 3 x greater flux), whilst for the NaKCl cotrans- 
porter these two ions are more or less equal in their 
ability to support K+ transporter [l]. 
The inhibitors H25 and H74 resolve the two 
Cl--dependent K+-transport pathways, providing a 
convenient alternative to swelling-shrinking or 
Cl--replacement protocols for defining KC1 
cotransport in cells. This distinction provides good 
evidence for the separate identity of these two 
transporters, and should facilitate the study of KC1 
cotransport. 
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Fig.2. The effect of H25 and H74 as inhibitors of either (a) KC1 or (b) NaKCl cotransport. The Vo inhibition of K+ influx was calculated from 
four experiments imilar to fig.1, but using different appropriate inhibitor concentrations. Results are pooled from data obtained from 4 separate 
donors (3 haemochromatosis and 1 HbSS patient for the H25 data, and 2 haemochromatosis and one HbSS patient for the H74 data). 
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